StreetInsider.com News Articles

Form S-8 Astrana Health, Inc.

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635884.html

Form S-8 Astrana Health, Inc.

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635884.html

Form 8-K Astrana Health, Inc. For: Jun 10

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630097.html

Form 8-K Astrana Health, Inc. For: Jun 10

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630097.html

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

ALHAMBRA, Calif., June 4, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced it has been named to the Fortune 1000® for 2026, marking its debut on the annual ranking of the largest U.S. companies by revenue. The recognition reflects Astrana's continued growth and momentum as it builds AI-powered healthcare infrastructure that helps providers deliver more accessible, coordinated, and affordable care.

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Thu, 04 Jun 2026 17:00:00 -0400

Barclays Upgrades Astrana Health, Inc (ASTH) to Overweight

Tue, 26 May 2026 07:21:46 -0400

Barclays analyst Andrew Mok upgraded Astrana Health, Inc (NASDAQ: ASTH) from Equalweight to Overweight with a price target of $50.00 (from $37.00).

For an analyst ratings summary and ratings history on Astrana Health, Inc click here. For more ratings news on Astrana Health, Inc click here.

Shares of Astrana Health, Inc closed at $37.85 yesterday.

Barclays Upgrades Astrana Health, Inc (ASTH) to Overweight

Tue, 26 May 2026 07:21:46 -0400

Barclays analyst Andrew Mok upgraded Astrana Health, Inc (NASDAQ: ASTH) from Equalweight to Overweight with a price target of $50.00 (from $37.00).

For an analyst ratings summary and ratings history on Astrana Health, Inc click here. For more ratings news on Astrana Health, Inc click here.

Shares of Astrana Health, Inc closed at $37.85 yesterday.

Form 4 Astrana Health, Inc. For: May 16 Filed by: Basho Chandan

Mon, 18 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26514026.html

Form 4 Astrana Health, Inc. For: May 16 Filed by: Basho Chandan

Mon, 18 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26514026.html

Form 4 Astrana Health, Inc. For: May 16 Filed by: Basho Chandan

Mon, 18 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260518/26514026.html

Astrana Health, Inc (ASTH) PT Raised to $47 at Truist Securities

Thu, 14 May 2026 04:27:25 -0400

Truist Securities analyst Jailendra Singh raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $47.00 (from $38.00) while maintaining a Buy rating.

The analyst comments "We had a post-quarterly call with ASTH management to discuss 1Q26 results, Prospect performance, its 2026 outlook, thoughts on 2027, among other topics. In the text below, we list our questions and the company’s responses. The answers are not verbatim, but we put the company’s answers in their proper context in a give and take format. With this note, we are raising our PT to $47 (vs. $38 previously)."

Astrana Health, Inc (ASTH) PT Raised to $47 at Truist Securities

Thu, 14 May 2026 04:27:25 -0400

Truist Securities analyst Jailendra Singh raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $47.00 (from $38.00) while maintaining a Buy rating.

Astrana Health appoints George Christides as interim medical director

Tue, 12 May 2026 16:06:52 -0400

Astrana Health, Inc. (NASDAQ: ASTH) announced the appointment of George Christides, M.D. as Interim National Medical Director on May 12, 2026, according to a company statement.

Dr. Christides will oversee the company's population health, care management, and care navigation initiatives across its national platform. He brings more than 20 years of clinical and healthcare leadership experience in value-based care, population health, and managed care operations.

Prior to this appointment, Dr. Christides served as Senior Medical Director, Population Health at Astrana, where he led clinical and population health initiatives across the organization. Before joining Astrana, he held positions as Senior Medical Director at

Astrana Health appoints George Christides as interim medical director

Tue, 12 May 2026 16:06:52 -0400

Astrana Health, Inc. (NASDAQ: ASTH) announced the appointment of George Christides, M.D. as Interim National Medical Director on May 12, 2026, according to a company statement.

Astrana Health, Inc. Announces Appointment of Interim National Medical Director